Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| In terms of highlights, IDEXX achieved solid revenue growth and strong profit gains in the third quarter |
| IDEXX VETLAB consumer revenues increased 11% organically with double digit gains in US and international regions |
| Organic revenue growth was supported by sustained benefits from IDEXX execution drivers including continued strong premium instrument replacements, solid new business gains, high levels of customer retention and high growth in recurring veterinary software revenues |
| Operating profit results were ahead of our expectations supported by gross margin gains and operating expense leverage, which enabled EPS delivery of $2.53 per share, up 18% as reported and 16% on a comparable basis |
| Not only have you delivered today in the third quarter, but your efforts position us well to continue to develop our sector and support our customers well into the future |
| This reflects expectations for strong comparable operating margin gains this year |
| Third quarter organic revenue growth of 8% was driven by 8% organic CAG gains and 7% organic growth in our Water business |
| CAG diagnostic recurring revenue increased 9% organically, reflecting 8.3% gains in the US and 10.3% growth in international regions net of a 0.5% global growth headwind from equivalent days effects |
| The other thing that I would point out is the, relative frequency and utilization of diagnostics continues to grow within the practice we've seen that in the US, we think that's a very positive trend |
| Overall, organic revenue growth was supported by 13% organic growth in veterinary software and diagnostic imaging revenues, driven by continued strong gains in recurring software revenues |
| IDEXX CAG diagnostic recurring revenue growth remains solidly above sector growth levels |
| Our sector remains very dynamic and your steadfast commitment to providing a better future for animals, people and our planet has helped us maintain momentum and deliver strong results |
| I think we're well positioned to capitalize on those trends and the practices just continued to work through some of the constraints we cited |
| Instrument benefits from IDEXX execution drivers, including higher net price realization, solid new business gains, and sustained high customer retention levels |
| The other piece that we've been spending time, looking at is just overall employment levels within the practice and we think that that has increased and that's in a good position |
| IDEXX international CAG diagnostic recurring revenue growth was 10.3% in Q3, reflecting continued benefits from higher net price realization, and improved volume gains |
| International results were also supported by strong IDEXX execution, reflected and sustained new business gains and high Q3 premium instrument replacements, which supported a double-digit expansion of our premium instrument installed base |
| So, I think from an industry standpoint, it's a very positive story |
| Globally Q3 results were supported by strong growth of IDEXX in-clinic CAG diagnostic recurring revenues |
| IDEXX software and data solutions situate us well to benefit from these trends, as well as the accretion in operating margin drop through associated with a revenue base that is increasingly recurring in nature |
| Consumer gains were supported by 11% year-on-year growth at our global premium instrument installed base, reflecting strong gains across our catalyst, premium hematology and set-of-you platforms |
| The quality of instrument replacements continues to be excellent reflected in solid global gains in EVI metrics and sustained high new and competitive catalyst placements in the US |
| ProCyte One installed base expansion continued at a solid pace reflected in a global installed base of over 12,000 instruments |
| Global Rapid Assay revenues expanded 8% organically in Q3, supported by strong growth in the U.S., including benefits from higher net price realization |
| Global lab revenues increased 7% organically, reflecting high single-digit gains in the U.S |
| and relatively improved mid-to-high single-digit growth in International regions |
| And then overall, our competitive position is very strong and we think as a result of our innovation pipeline, we will continue to be strong enough for some differentiated advantages |
| This reflects an outlook for 360 to 380 basis points in comparable operating margin expansion, including approximately 280 basis points in combined benefit from the $16 million Q1 customer contract resolution payment and the lapping of $80 million of discrete R&D investment in the second quarter of 2022 |
| The adoption of IDEXX technology is the long-term demand dynamics that we see associated with expanded population, and favorable demographics in terms of pet ownership |
| Growth was driven by continued solid gains in the U.S., including benefits from net price improvement |
| Statement |
|---|
| Software trends in Q3 a period of an impacted by ongoing capacity management challenges at US clinics, including effects from high staff turnover |
| This was below our expectations for relatively flattening US clinic visit trends, reflecting ongoing capacity management challenges at US clinics and relatively softer wellness visit levels |
| GAC instrument revenues were down 10% organically, reflecting comparisons to high priority levels, program pricing effects and global mix |
| As noted, same-store US clinic visit declines of 2% were below our expectations for relatively flat clinic visit growth in the second half of 2023 |
| Our Q4 outlook also incorporates a 1% equivalent day volume growth headwind |
| I think the thing that we're working through is a combination of near-term capacity management challenges at the clinics |
| continue to be moderated by constraints on International growth, including impacts from lower herd health screening revenues related to reduced China import testing |
| Overall, organic revenue growth was moderated by 2% organic growth in our LPD business and approximately $3 million of headwind related to lower opti medical revenues including effects from the wind down of our human COVID testing business |
| If this continues without anything that's improvement, how does this impact your long-term model and longer term expectations to the business? Already put another way, you're targeting 8.5% organic growth this year well below your 10%, long-term target and that's despite taking 7% to 8% price |
| Our organic growth guidance assumes a level of continued pressure on U.S |
| Global catalyst placements decreased 2% overall reflecting tough comparisons to high prior year international placement levels |
| We also saw a relative slow down in wellness visits in the quarter, which may reflect some macro impacts on demand at the clinic level |
| The 2Q to 3Q was down 3% to 4% |
| We're projecting an approximate 70 basis point gross margin headwind in Q4 related to FX, again primarily related to the lapping of prior year hedge gains |
| There are some constraints related to practice capacity and some challenges there |
| This reflects an approximately 1100 basis point normalized growth premium, compared to same-store US clinic visit growth levels, which declined an estimated 2% overall in the quarter |
| We are deeply saddened by the senseless act of violence impacting our communities |
| I think it's a, we did see some relative softening through the quarter |
| Overall CAG diagnostics recurring revenue gains in the quarter were moderated by a 2% same-store decline in US clinical business |
| We now estimate that foreign exchange impacts will decrease EPS by $0.25 per share for the full year and will reduce reported full year operating margins by 70 basis points including impacts from the lapping of $26 million in 2022 hedge gains |
Please consider a small donation if you think this website provides you with relevant information